U.S. Markets open in 6 hrs 20 mins

Rubius (RUBY) in Focus: Stock Moves 8.7% Higher

Zacks Equity Research
1 / 2

Magellan Midstream (MMP) Beats on Q3 Earnings and Sales

Magellan Midstream's (MMP) DCF in the third quarter of 2018 rises 19.8% from the year-ago level.

Rubius Therapeutics, Inc. RUBY was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 9.2% in the past one-month time frame.

The company has seen two negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So, make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Rubius currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Rubius Therapeutics, Inc. Price

Rubius Therapeutics, Inc. Price | Rubius Therapeutics, Inc. Quote

Investors interested in the Medical - Biomedical and Genetics industry may consider Gilead Sciences, Inc. GILD, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is RUBY going up? Or down? Predict to see what others think:Up or Down

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
 
Rubius Therapeutics, Inc. (RUBY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research